Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Precision oncology therapies are increasingly used for cancer treatment.
• Drug-related pneumonitis is a potential adverse event associated with these therapies.
• Early recognition and diagnosis of pneumonitis are critical.

Purpose of the Study:

• To provide an updated review on drug-related pneumonitis in patients undergoing precision oncology.
• To focus on newly approved oncologic agents, particularly antibody-drug conjugates.
• To detail the incidence, onset timing, and imaging findings of pneumonitis.

Main Methods:

• Literature review of recent studies on precision oncology agents and pneumonitis.
• Analysis of reported cases of drug-related pneumonitis.
• Focus on incidence, timing, and characteristic imaging patterns.

Main Results:

• Newly approved precision oncology agents, including antibody-drug conjugates, are associated with drug-related pneumonitis.
• Pneumonitis can manifest with varying incidence and onset times.
• Specific imaging patterns are observed in drug-induced pneumonitis.

Conclusions:

• Clinicians must maintain a high index of suspicion for drug-related pneumonitis with new cancer therapies.
• Understanding the incidence, timing, and imaging is key for timely diagnosis and management.
• This review updates knowledge on pneumonitis associated with novel precision oncology agents.